New York City Department of Health and Mental Hygiene, 42-09 28th Street, Long Island City, NY, 11101, USA.
Harm Reduct J. 2023 Mar 25;20(1):38. doi: 10.1186/s12954-023-00772-3.
Since the emergence of fentanyl in the drug market, syringe services programs (SSPs) have been at the forefront of providing life-saving tools such as naloxone and fentanyl test strips to people who use drugs (PWUD). It is still unclear, however, how the adoption of risk-reduction practices has differed among PWUD in the context of increasing presence of non-pharmaceutical fentanyl in the drug supply. This study aims to assess the adoption of risk-reduction tools (e.g., naloxone) among those engaged with SSP services and those not engaged with SSP services.
We conducted a mixed-methods study following a convergent parallel design integrating both quantitative and qualitative data. Interviews were conducted with 80 people who used street opioids (i.e., heroin or opioid pills not prescribed), 32 of whom were not engaged in SSP services. Quantitative differences between those engaged and those not engaged in SSPs were assessed using independent samples t tests and Fisher's exact tests. A thematic analytic approach was employed to compare qualitative responses between the two groups.
Three main themes emerged in our analysis: (1) Both groups expressed an interest in fentanyl test strips (FTS), but those engaged in SSP services found them to be more accessible; (2) there was greater adoption of and enthusiasm for naloxone among SSP participants; and (3) SSP participants were more likely to have or be interested in having someone check in on them when using alone, but stigma and perceived personal risk of overdose prevented widespread adoption of this practice among all participants.
SSPs provide a vital function by facilitating naloxone and FTS distribution to participants who often have little control over their exposure to fentanyl. However, stigma and misconceptions regarding drug use are barriers to people adopting risk-reduction practices, particularly among those not engaged with SSPs.
自芬太尼出现在毒品市场以来,注射吸毒者服务项目(SSP)一直处于提供救命工具(如纳洛酮和芬太尼检测条)的前沿,这些工具提供给吸毒者(PWUD)。然而,在药物供应中越来越多的非药物芬太尼的情况下,PWUD 之间减少风险做法的采用情况仍不清楚。本研究旨在评估那些接受 SSP 服务的人与那些不接受 SSP 服务的人采用减少风险工具(如纳洛酮)的情况。
我们采用收敛平行设计,综合了定量和定性数据,进行了一项混合方法研究。我们对 80 名吸食街头阿片类药物(即未处方的海洛因或阿片类药丸)的人进行了访谈,其中 32 人未接受 SSP 服务。使用独立样本 t 检验和 Fisher 精确检验评估了接受 SSP 服务和不接受 SSP 服务的两组之间的定量差异。采用主题分析方法比较了两组之间的定性反应。
我们的分析中出现了三个主要主题:(1)两组都对芬太尼检测条(FTS)感兴趣,但接受 SSP 服务的人发现它们更容易获得;(2)SSP 参与者更愿意接受并热衷于使用纳洛酮;(3)SSP 参与者更有可能在独自使用时有人检查他们,但污名化和对药物过量的个人风险的认知,阻止了所有参与者广泛采用这种做法。
SSP 通过促进纳洛酮和 FTS 的分发,为参与者提供了重要的功能,而这些参与者往往对接触芬太尼的控制能力很小。然而,对吸毒的污名化和误解是人们采用减少风险做法的障碍,尤其是那些不接受 SSP 服务的人。